Senti Biosciences, Inc.

NasdaqCM:SNTI Stock Report

Market Cap: US$19.1m

Senti Biosciences Management

Management criteria checks 1/4

Senti Biosciences' CEO is Tim Lu, appointed in Jul 2016, has a tenure of 8.42 years. total yearly compensation is $1.69M, comprised of 36% salary and 64% bonuses, including company stock and options. directly owns 3.52% of the company’s shares, worth $673.99K. The average tenure of the management team and the board of directors is 0.6 years and 3.3 years respectively.

Key information

Tim Lu

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage36.0%
CEO tenure8.4yrs
CEO ownership3.5%
Management average tenureless than a year
Board average tenure3.3yrs

Recent management updates

Recent updates

Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?

Dec 28
Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?

Will Senti Biosciences (NASDAQ:SNTI) Spend Its Cash Wisely?

Sep 27
Will Senti Biosciences (NASDAQ:SNTI) Spend Its Cash Wisely?

Senti Biosciences initiated at buy at Chardan on gene circuit synthetic biology platform

Sep 22

Senti Biosciences GAAP EPS of -$0.86, revenue of $1.36M

Aug 16

Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?

Jun 13
Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?

CEO Compensation Analysis

How has Tim Lu's remuneration changed compared to Senti Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$71m

Jun 30 2024n/an/a

-US$79m

Mar 31 2024n/an/a

-US$82m

Dec 31 2023US$2mUS$607k

-US$83m

Sep 30 2023n/an/a

-US$80m

Jun 30 2023n/an/a

-US$54m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$811kUS$538k

-US$50m

Sep 30 2022n/an/a

-US$46m

Jun 30 2022n/an/a

-US$46m

Mar 31 2022n/an/a

-US$46m

Dec 31 2021US$24mUS$475k

-US$55m

Compensation vs Market: Tim's total compensation ($USD1.69M) is above average for companies of similar size in the US market ($USD650.00K).

Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.

CEO

Tim Lu (43 yo)

8.4yrs

Tenure

US$1,686,498

Compensation

Dr. Timothy K. Lu, also known as Tim, Ph D., M.D., is Member of Scientific Advisory Board of Integrated Biosciences, Inc. He served as Member of Scientific Advisory Board at Absci Corporation since Februar...

Leadership Team

NamePositionTenureCompensationOwnership
Timothy Lu
Co-Founder8.4yrsUS$1.69m3.52%
$ 674.0k
Kanya Rajangam
Presidentless than a yearUS$858.77k0%
$ 0
James Collins
Scientific Co-Founderno dataUS$107.70k0.38%
$ 73.4k
Wilson Wong
Scientific Co-Founder & Member of Scientific Advisory Boardno datano datano data
Yvonne Li
Interim CFOless than a yearno datano data
Thomas Chung
Vice President of Strategic Finance & Corporate Developmentless than a yearno datano data
Dee Dragon
VP of People & Culture Strategy & Head of Administrative Operationsless than a yearno datano data

0.6yrs

Average Tenure

54.5yo

Average Age

Experienced Management: SNTI's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Timothy Lu
Co-Founder8.5yrsUS$1.69m3.52%
$ 674.0k
James Collins
Scientific Co-Founder3.3yrsUS$107.70k0.38%
$ 73.4k
Wilson Wong
Scientific Co-Founder & Member of Scientific Advisory Boardno datano datano data
Michael Varney
Member of Scientific Advisory Board3.3yrsno datano data
Edward Mathers
Independent Director8.4yrsUS$94.72k0%
$ 0
Michael Andreeff
Member of Scientific Advisory Boardno datano datano data
Martin Fussenegger
Member of Scientific Advisory Boardno datano datano data
Brenda Cooperstone
Independent Director5.2yrsUS$94.22k0%
$ 0
Lawrence Fong
Member of Scientific Advisory Boardno datano datano data
Fran Schulz
Directorno datano datano data
Ahmad Khalil
Member of Scientific Advisory Boardno datano datano data
Michael Kalos
Member of Scientific Advisory Board3.3yrsno datano data

3.3yrs

Average Tenure

59yo

Average Age

Experienced Board: SNTI's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 19:59
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Senti Biosciences, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gregory HarrisonBofA Global Research
Yevgeniya LivshitsChardan Capital Markets, LLC
Lut Ming ChengJ.P. Morgan